Drug Makers Duke It Out Over Smallpox Vaccine Patent

Law360, New York (August 22, 2005, 12:00 AM EDT) -- The U.S. government’s desire to protect citizens from a biological terrorist attack has triggered patent litigation between two European drug makers, both leading producers of smallpox vaccinations.

Denmark-based Bavarian Nordic and United Kingdom-based Acambis Inc. are the only two companies working on a specially-weakened, hence safer, version of the smallpox vaccine. Bavarian alleges Acambis is producing its version of the weakened vaccine with stolen research, taking its complaint to the U.S. International Trade Commission Friday.

Bavarian also filed a trade secrets suit in U.S. District Court...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.